Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
This study will determine whether or not Lenalidomide improves effectiveness of treatment for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the disease (bendamustine and rituximab).
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Maintenance Therapy With Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia|
- Response rate [ Time Frame: 36 months ] [ Designated as safety issue: No ]NCI sponsored Working Group Guidelines for CLL
- Adverse events [ Time Frame: 36 months ] [ Designated as safety issue: Yes ]Physical examination, blood counts.
|Study Start Date:||March 2012|
|Estimated Study Completion Date:||March 2016|
|Estimated Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|
Maintenance treatment with lenalidomide following induction treatment with bendamustine and rituximab.
Drug: Maintenance lenalidomide
Daily maintenance treatment, oral lenalidomide
|United States, Connecticut|
|Yale Cancer Center||Recruiting|
|New Haven, Connecticut, United States, 06519|
|Contact: Molly Daley 203-785-5702 email@example.com|
|Contact: Diana Irizarry, RN 203-737-2451 firstname.lastname@example.org|
|Principal Investigator:||Terri L Parker, MD||Yale University|